Cytotoxic chemotherapy for differentiated thyroid carcinoma

Clinical Oncology

Volumn 22, Issue 6, 2010, Pages 464-468

  Sherman, S I ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Chemotherapy; Thyroid neoplasia

Indexed keywords

ACLARUBICIN; ALPHA2B INTERFERON; BLEOMYCIN; CAPECITABINE; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; ENZASTAURIN; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; GEMCITABINE; MELPHALAN; METHOTREXATE; MITOXANTRONE; PACLITAXEL; PEMETREXED; RADIOACTIVE IODINE; VINCRISTINE; ANTINEOPLASTIC AGENT; GLUTAMIC ACID DERIVATIVE; GUANINE;

ADVANCED CANCER; ALOPECIA; ANOREXIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RELAPSE; CARDIOMYOPATHY; CARDIOTOXICITY; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DIFFERENTIATED THYROID CARCINOMA; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG TOLERABILITY; FATIGUE; GRANULOCYTOPENIA; HEART ARRHYTHMIA; HUMAN; LEUKOPENIA; LOW DRUG DOSE; LUNG METASTASIS; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAIL COLOR DEFECT; NAIL DISEASE; NAUSEA; NAUSEA AND VOMITING; NEPHROTOXICITY; NEUROPATHY; NEUTROPENIA; OUTCOME ASSESSMENT; PARESTHESIA; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RESPIRATORY FAILURE; RETROSPECTIVE STUDY; SKIN DISCOLORATION; THORAX RADIOGRAPHY; THROMBOCYTOPENIA; THYROID CANCER; THYROID CARCINOMA; THYROID FOLLICULAR CARCINOMA; THYROID MEDULLARY CARCINOMA; THYROID PAPILLARY CARCINOMA; TREATMENT DURATION; TREATMENT RESPONSE; VOMITING; ANALOGS AND DERIVATIVES; CLINICAL TRIAL (TOPIC); PATHOLOGY; PATIENT PARTICIPATION; THYROID NEOPLASMS; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; CLINICAL TRIALS AS TOPIC; DOXORUBICIN; ETOPOSIDE; GLUTAMATES; GUANINE; HUMANS; PATIENT PARTICIPATION; THYROID NEOPLASMS; TREATMENT OUTCOME;

EID: 77954762933     PISSN: 09366555     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clon.2010.03.014     Document Type: Article

References (34)

1. Poster D.S., Bruno S., Penta J., Pina K., Catane R. Current status of chemotherapy in the treatment of advanced carcinoma of the thyroid gland. Cancer Clin Trials 1981, 4:301-307.
2. Sherman S.I. Clinical trials for thyroid carcinoma: past, present, and future. Practical management of thyroid cancer: a multidisciplinary approach 2006, 429-434. Springer, London. E.L. Mazzaferri, C. Harmer, U.K. Mallick, P. Kendall-Taylor (Eds.).
3. Braga-Basaria M., Ringel M.D. Beyond radioiodine: a review of potential new therapeutic approaches for thyroid cancer. J Clin Endocrinol Metab 2003, 88:1947-1960.
4. Schweppe R.E., Klopper J.P., Korch C., et al. DNA profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification. J Clin Endocrinol Metab 2008, 93(11):4331-4341.
5. Tsimberidou A.M., Vaklavas C., Wen S., et al. Phase I clinical trials in 56 patients with thyroid cancer: the M.D. Anderson Cancer Center experience. J Clin Endocrinol Metab 2009, 94(11):4423-4432.
6. Harada T., Nishikawa Y., Suzuki T., Ito K., Baba S. Bleomycin treatment for cancer of the thyroid. Am J Surg 1971, 122:53-57.
7. Bonadonna G., Monfardini S., De Lena M., Fossati-Bellani F., Beretta G. Phase I and preliminary phase II evaluation of adriamycin (NSC 123127). Cancer Res 1970, 30:2572-2582.
8. Gottlieb J.A., Hill C.S., Ibanez M.L., Clark R.L. Chemotherapy of thyroid cancer. An evaluation of experience with 37 patients. Cancer 1972, 30:848-853.
9. Gottlieb J.A., Hill C.S. Chemotherapy of thyroid cancer with adriamycin: experience with 30 patients. N Engl J Med 1974, 290:193-197.
10. Burgess M.A., Hill C.S. Chemotherapy in the management of thyroid cancer. Thyroid cancer 1978, 233-245. CRC Press, W. Palm Beach. L.D. Greenfield (Ed.).
11. Haugen B.R. Management of the patient with progressive radioiodine non-responsive disease. Semin Surg Oncol 1999, 16:34-41.
12. Matuszczyk A., Petersenn S., Bockisch A., et al. Chemotherapy with doxorubicin in progressive medullary and thyroid carcinoma of the follicular epithelium. Horm Metab Res 2008, 40:210-213.
13. Gottlieb J.A., Drewinko B. Review of the current clinical status of platinum coordination complexes in cancer chemotherapy. Cancer Chemother Rep 1975, 59:621-628.
14. Rozencweig M., Nicaise C., Beer M., et al. Phase I study of carboplatin given on a five-day intravenous schedule. J Clin Oncol 1983, 1:621-626.
15. Joss R.A., Kaplan S., Goldhirsch A., Sessa C., Brunner K.W., Cavalli F. A phase I trial of cis-diammine-1,1-cyclobutane dicarboxylate platinum II (Carboplatin, CBDCA, JM-8) with a single dose every five week-schedule. Invest New Drugs 1984, 2:297-304.
16. Hoskin P.J., Harmer C. Chemotherapy for thyroid cancer. Radiother Oncol 1987, 10:187-194.
17. Droz J.P., Schlumberger M., Rougier P., Ghosn M., Gardet P., Parmentier C. Chemotherapy in metastatic nonanaplastic thyroid cancer: experience at the Institut Gustave-Roussy. Tumori 1990, 76:480-483.
18. Leaf A.N., Wolf B.C., Kirkwood J.M., Haselow R.E. Phase II study of etoposide (VP-16) in patients with thyroid cancer with no prior chemotherapy: an Eastern Cooperative Oncology Group study (E1385). Med Oncol 2000, 17:47-51.
19. Shimaoka K., Schoenfeld D.A., DeWys W.D., Creech R.H., DeConti R. A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma. Cancer 1985, 56:2155-2160.
20. Williams S.D., Birch R., Einhorn L.H. Phase II evaluation of doxorubicin plus cisplatin in advanced thyroid cancer: a Southeastern Cancer Study Group Trial. Cancer Treat Rep 1986, 70:405-407.
21. Bukowski R.M., Brown L., Weick J.K., Groppe C.W., Purvis J. Combination chemotherapy of metastatic thyroid cancer. Phase II study. Am J Clin Oncol 1983, 6:579-581.
22. Argiris A., Agarwala S.S., Karamouzis M.V., Burmeister L.A., Carty S.E. A phase II trial of doxorubicin and interferon alpha 2b in advanced, non-medullary thyroid cancer. Invest New Drugs 2007, 26:183-188.
23. Biganzoli L., Gebbia V., Maiorino L., Caraci P., Iirillo A. Thyroid cancer: different outcomes to chemotherapy according to tumour histology. Eur J Cancer 1995, 31A:2423-2424.
24. Santini F., Bottici V., Elisei R., et al. Cytotoxic effects of carboplatinum and epirubicin in the setting of an elevated serum thyrotropin for advanced poorly differentiated thyroid cancer. J Clin Endocrinol Metab 2002, 87:4160-4165.
25. Ain K.B., Egorin M.J., DeSimone P.A. Treatment of anaplastic thyroid carcinoma with paclitaxel: phase 2 trial using ninety-six-hour infusion. Thyroid 2000, 10:587-594.
26. Ikeda M., Tanaka K., Sonoo H., et al. Docetaxel administration for radioiodine-resistant patients with metastatic papillary thyroid carcinoma. Gan To Kagaku Ryoho 2007, 34:933-936.
27. Matuszczyk A., Petersenn S., Voigt W., et al. Chemotherapy with paclitaxel and gemcitabine in progressive medullary and thyroid carcinoma of the follicular epithelium. Horm Metab Res 2010, 42:61-64.
28. Hanauske A.R., Lahn M., Musib L.C., et al. Phase Ib safety and pharmacokinetic evaluation of daily and twice daily oral enzastaurin in combination with pemetrexed in advanced/metastatic cancer. Ann Oncol 2009, 20:1565-1575.
29. Hanauske A.-R., Dumez H., Piccart M., et al. Pemetrexed combined with paclitaxel: a dose-finding study evaluating three schedules in solid tumors. Invest New Drugs 2009, 27:356-365.
30. Saller B. Treatment with cytotoxic drugs. Thyroid cancer 2005, 171-186. Springer, [Chapter 10]. H. Biersack, F. Grunwald (Eds.).
31. Gilliam L.K., Kohn A.D., Lalani T., et al. Capecitabine therapy for refractory metastatic thyroid carcinoma: a case series. Thyroid 2006, 16(8):801-810.
32. Alexandre J., Kahatt C., Bertheault-Cvitkovic F., et al. A phase I and pharmacokinetic study of irofulven and capecitabine administered every 2 weeks in patients with advanced solid tumors. Invest New Drugs 2007, 25(5):453-462.
33. Klonisch T., Hoang-Vu C., Hombach-Klonisch S. Thyroid stem cells and cancer. Thyroid 2009, 19(12):1303-1315.
34. Schlumberger M., Sherman S.I. Clinical trials for progressive differentiated thyroid cancer: patient selection, study design, and recent advances. Thyroid 2009, 19:1393-1400.